2025 annual financial data
China SXT Pharmaceuticals 2025 Operating margin
China SXT Pharmaceuticals 2025 operating margin with verified reported values.
Direct answer
Operating margin was -153.97%.
Operating income was -2,680,479 USD and net income was -3,303,652 USD.
Operating cash flow was -2,345,333 USD.
Get free China SXT Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 1,740,907 USD
- Operating income
- -2,680,479 USD
- Net income
- -3,303,652 USD
- Operating cash flow
- -2,345,333 USD